DLA Piper advises Akoya Biosciences in its US$151 million initial public offering
On May 3, 2021, Akoya Biosciences (Nasdaq: AKYA) completed its initial public offering (IPO) by issuing 7,567,000 shares at $20 per share, raising approximately $151 million. This offering included the underwriters' option to purchase an additional 987,000 shares. Akoya specializes in single-cell imaging solutions, utilizing its CODEX® and Phenoptics™ platforms to enhance research in disease progression and treatment response. DLA Piper facilitated this transaction, leveraging its expertise in capital markets and life sciences.
- Raised approximately $151 million from the IPO.
- The successful inclusion of underwriters' option reflects strong investor interest.
- The issuance of 7,567,000 shares may lead to shareholder dilution.
NEW YORK, May 3, 2021 /PRNewswire/ -- DLA Piper represented Akoya Biosciences, Inc. (Nasdaq: AKYA) in its recent initial public offering of 7,567,000 shares of its common stock at a price of
Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.
"We were pleased to bring together our extensive capital markets and life sciences sector experience to help Akoya achieve its goals in this transaction," said Michael Kagnoff, the DLA Piper partner who led the firm's deal team.
In addition to Kagnoff (San Diego), the DLA Piper team advising Akoya included partners Patrick O'Malley (San Diego), Rebecca McKnight (Austin), Cathryn Le Regulski (Northern Virginia), William Bartow (Philadelphia) and Mark Muedeking (Washington, DC); and associates Bianca LaCaille (Seattle), Zamzama Azizi (San Diego), Sarah Thompson Schick (Austin) and Priya Narahari (Philadelphia).
DLA Piper's global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients' needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com
View original content:http://www.prnewswire.com/news-releases/dla-piper-advises-akoya-biosciences-in-its-us151-million-initial-public-offering-301282279.html
SOURCE DLA Piper
FAQ
What was the share price of Akoya's IPO on May 3, 2021?
How many shares did Akoya Biosciences issue in its IPO?
What is the total amount raised by Akoya in its IPO?
What are the primary solutions offered by Akoya Biosciences?
What does the underwriters' option in Akoya's IPO signify?
